O xygen supply declines under ischemic conditions in many human vascular diseases including ischemic heart disease, chronic kidney failure, and stroke. The resulting hypoxia causes functional impairment of cells as well as structural tissue damage and triggers a broad spectrum of cellular defenses such as angiogenesis, erythropoiesis, glycolysis, and antioxidative enzymes.
Hypoxia-inducible factor (HIF), a heterodimeric nuclear factor, is a crucial intermediate in these defensive mechanisms. [1] [2] [3] Under normoxic conditions, HIF is constitutively transcribed and translated. Its stability is drastically reduced by the oxygen-dependent enzymatic hydroxylation of proline residues by prolyl hydroxylases (PHD). 4 -9 Hydroxylated HIF recruits the E3-ubiquitin ligase, von Hippel Lindau protein (pVHL) 10, 11 which, in turn, tags HIF with ubiquitin groups and targets it for degradation by the proteasome. 12, 13 Under hypoxic conditions, HIF is not hydroxylated but binds to its heterodimeric partner HIF-1␤. The resulting protein complex transactivates in the nucleus a host of genes involved in the adaptation to hypoxic stress. 14 Activation of HIF may prove therapeutic for vascular disorders. Most treatments for ischemic and hypoxic disorders are currently focused on symptomatic relief and correction of etiologic factors. Drugs dissolving thrombi are also used to restore blood flow in the acute phase. As yet no compound enhancing organ resistance to hypoxia is clinically available. HIF activates a "master gene" switch that results in a broad and coordinated downstream reaction, protecting tissues against the consequences of hypoxia. The availability of less cumbersome non-toxic small molecular activators of HIF should prove very useful for therapeutic intervention. 15, 16 To obtain such novel compounds and to understand a molecular mechanism of PHD inhibition, we performed docking simulation based on the 3-dimensional structure of human PHD2. We further documented the in vitro and in vivo effectiveness of the novel PHD inhibitors we identified.
Materials and Methods

Docking Simulations
The X-ray crystal structure of human PHD2 was obtained from the Protein Data Bank 17 (PDB code: 2HBT) . Throughout the present study, the software system MOE (Molecular Operating Environment, version 2005.06) and the MMFF94s force field 18 were used. Binding sites were characterized using the alpha site finder function 19 in MOE. The docking of small molecules and the target sites was performed by the program Ph4Dock. 20 
PHD Activity
PHD activity was determined as described by Kaule et al. 21 In brief, mitochondrial fraction of IRPTC homogenates was reacted with the tested compounds and ODD peptide of HIF-1␣. ODD-dependent hydroxylase activity was assessed by counting the radioactivity of [1- 14 C]-succinate converted from [5-14 C]-2-OG by PHD.
Transition Metal Chelation
The chelating activity of the tested compounds for transition metal ions was measured by the method of Price et al 22 with some modifications.
Capillary Network Formation
Capillary network formation was examined by Matrigel assays (BD Biosciences) as described previously. 23 
Sponge Assays
Sponge angiogenesis assays were performed as described previously. 24
Hypoxia-Sensing Transgenic Rat
Stimulation of the HIF-HRE system by systemic administration of TM6008 or TM6089 was evaluated using the hypoxia-sensing transgenic rat strain. 24 Expression of the hypoxia-responsive luciferase gene was estimated by semiquantitative RT-PCR as described previously. 25 
Cerebral Ischemic Injury Model
Transient global ischemia of Mongolian gerbils was achieved by bilateral carotid occlusion. 26 Animals were then randomly divided into 3 experimental groups: Groups 1 (TM6008) and 2 (vehicle) animals underwent transient global ischemia. Group 3 animals were sham-operated and served as controls. We also measured cortical microperfusion by laser-Doppler flowmetry in gerbil forebrain ischemia treated with TM6008 or vehicle.
Statistics
Differences among groups were assessed by Kruskal-Wallis test or ANOVA. The statistical significance was determined by 2-tailed Mann-Whitney U test or Student t test. Data are expressed as meansϮSD. Values are considered significant at PϽ0.05.
Results
Identification of Novel HIF-Stimulating Compounds
Thirty-seven compounds that have structural similarities to FG-0041, a previously reported PHD inhibitor supposedly acting through iron chelation, 27 were selected from a chemical database. The chemical structures of these compounds are shown in supplemental Figure I . Their HIF-stimulating activity was tested by an in vitro screening assay which used cells expressing luciferase controlled by hypoxia responsive element (HRE) (supplemental Figure II) . Cobalt, a well known chemical mimicker of hypoxia by stabilizing HIF-␣ subunit, 28 was used as a positive control. Two derivatives, TM6008 and TM6089, exhibited strong HIF-stimulating activities ( Figure 1 ). TM6008 is 6-amino-1, 3-di methyl-5-(2-pyridin-2-yl-quinoline-4-carbonyl)-1H-pyrimidine-2, 4-dione, and TM6089 is 6-amino-1,
PHD Inhibition
The inhibitory effect of our compounds on the oxygendependent hydroxylation of HIF-␣ subunit by PHD was evaluated. All tested compounds inhibited PHD activity in a dose-dependent manner (Figure 2 ). TM6008 was the most effective, exceeding cobalt chloride.
In Vitro Transition Metal Chelation of PHD Inhibitors
Previously reported PHD inhibitors, such as 3,4-DHB, 29 S956711, 29 and FG-0041, 27 share an iron chelating motif. Although chemical structures of TM6008 and TM6089 differ significantly from previous PHD inhibitors, TM6008 also share this motif. By contrast, TM6089 lacks this motif.
We therefore evaluated their abilities to chelate transition metals in vitro by copper-catalyzed oxidation of ascorbic acid. 3,4-DHB, S965711, and TM6008 chelated transition 
Binding Mode to Human PHD
PHD produces trans-4-hydroxyproline from 2-OG and L-proline (Pro) in the presence of Fe(II). The crystal structure of the catalytic domain of human PHD2, an important prolyl-4-hydroxylase in the human hypoxia response in normal cells, has been recently reported. 30 Based on the 3-dimensional structure of this PHD, we undertook docking simulations between our 2 PHD inhibitors and human PHD2. The docking modes of TM6008 and TM6089 are shown in Figure 3 . TM6008 binds to the active site of PHD2 by chelating 2 nitrogen atoms with the iron atom. By contrast, TM6089 binds to the active site by nonchelating mechanism. The sulfur and 1 carbonyl oxygen atom of TM6089 point to the iron atom. The disposition of these 3 atoms, however, is unfavorable to form coordinate bonds. The binding mode of TM6089 demonstrates that TM6089 is a unique inhibitor without iron chelating affinity.
Toxicity and Pharmacokinetics
TM6008 and TM6089 did not exhibit cytotoxicity at the tested concentrations (up to 100 mol/L). No acute toxicity was observed in mice up to 2 weeks after a single oral dose of 2000 mg/kg for TM6008, whereas the 50% lethal dose of TM6089 was 500 mg/kg. Pharmacokinetics studies in rats given an oral dose of 50 mg/kg of each compound disclosed plasma Tmax, Cmax, and T1/2 values of 3.5 hour, 0.9 g/mL and 1.5 hour for TM6008, and 1.0 hour, 0.5 g/mL, and 0.6 hour for TM6089.
Demonstration of the In Vivo Effectiveness
As VEGF is regulated by the HIF-HRE system, we examined whether TM6008 and TM6089 stimulate angiogenesis.
Firstly, we examined whether local injection of our compounds stimulates angiogenesis in vivo. For this purpose, we introduced small sponges under the skin of mice and measured their hemoglobin contents and vessel numbers after 10 days to estimate the stimulation of the HIF-HRE system. Injection of TM6008 increased angiogenesis as demonstrated by an increase of the hemoglobin content, and by an increased vessel number on immunohistochemical evaluation of the sponges. TM6089 also enhanced angiogenesis in the sponge assays ( Figure 4A through 4C).
To investigate whether systemic administration of TM6008 and TM6089 stimulates in vivo the HIF-HRE system in various organs, we used the hypoxia-sensing transgenic rats. In the kidney expression of the reporter gene was not detected under basal conditions (amplification of 40 cycles), but expression of the reporter gene was obviously induced after a single oral dose 100 mg/kg of TM6008 and TM6089 (detected at 31.0Ϯ0.85 cycles and 31.0Ϯ2.05 cycles, respectively). In the liver, expression of the reporter gene, which was undetectable under basal conditions, was also induced after TM6008 administration (detected at 32.3Ϯ0.35 cycles), whereas TM6089 was ineffective. In the heart, the reporter gene was detected under basal conditions and both TM6008 and TM6089 increased its expression (1.37Ϯ1.00 and 6.69Ϯ5.45 fold increase, respectively). No attempt was made to evaluate the expression of the transgene in the brain because the pharmacokinetics studies showed that neither of the tested compounds crossed the blood-brain barrier.
Next, we evaluated capillary network formation by Matrigel assays. When endothelial cells were seeded onto Matrigel at subconfluent density, they developed tube-like structures at 9 hours. Quantification of capillary network formation by measuring the tube length revealed promotion of capillary network formation by TM6008, confirming the results of the sponge assays ( Figure 4D ). 
Prevention of Neuronal Cell Death Induced by Hypoxia
PHD inhibitors might protect cells against hypoxic damage. To test this hypothesis we used the delayed neuronal death model in gerbil. Nontoxic TM6008 (100 mg/kg/d) was given orally for 7 days in gerbils after a 5-minute transient global cerebral ischemia. The pathological outcome of neuronal cells was examined after 7 day administration of TM6008 in CA1 hippocampus with light microscopy.
In contrast with nonischemic gerbils (Figure 5A ), gerbils subjected to ischemia and given vehicle alone ( Figure 5B) exhibited in most pyramidal neurons ischemic cell damage, characterized by shrunken, darkly stained cytoplasm, and pyknotic nuclei with accumulation of glial cells. In the TM6008-treated animals, only a few neurons showed ischemic changes ( Figure 5C ). The number of viable neurons in the CA1 hippocampus, was higher in the TM6008-treated animals than in the vehicle-treated gerbils (166Ϯ73 versus 
61Ϯ55, PϽ0.05).
The number of viable neurons in the CA1 hippocampus of the TM6008-treated animals was not statistically different from that observed in the nonischemia control group (227Ϯ50). Further, treatment with TM6008 decreased the number of apoptotic cells ( Figure 5D ). The final plasma concentration of TM6008 in these experiments was 7.8Ϯ2.9 g/mL. Thus, TM6008 clearly protected against hypoxia-induced apoptotic neuronal death.
Next, we examined whether the protective effect of TM6008 against delayed neuronal death was attributable to enhanced angiogenesis. There was no statistically significant difference of the number of VEGF-positive cells between TM6008-and vehicle-treated groups (10.17Ϯ5.02 versus 9.12Ϯ1.55, respectively). Further, there was no significant difference of the value of cortical microperfusion at 7 days after occlusion between TM6008-and vehicle-treated groups (25.0Ϯ9.3 versus 29.4Ϯ8.7, respectively).
To clarify a neuroprotective mechanism of TM6008 in global ischemia models, we immunohistochemically stained with EPO, GLUT-1, and GLUT-3. The number of GLUT-3-positive cells in the CA1 hippocampus was significantly higher in TM6008 treated than in the vehicle-treated gerbils (26.9Ϯ7.5 versus 15.3Ϯ8.6, PϽ0.05). However, there was no statistically significant difference in EPO or GLUT-1-positive cells in the CA1 hippocampus between TM6008-and vehicle-treated groups (2.9Ϯ2.9 versus 3.3Ϯ1.7; and 5.5Ϯ2.1 versus 6.4Ϯ1.8, respectively).
Discussion
We identified novel molecules able to inhibit PHD activity and stabilize HIF. Our docking simulation studies based on the 3 dimensional structure of PHD2 have disclosed the molecular events required to inhibit PHD and therefore stabilize HIF. The target of these PHD inhibitors is the PHD active site.
Most of the PHD inhibitors reported so far, eg, 3,4-DHB, S956711 and FG-0041, are believed to inhibit the enzyme by iron chelating mechanism. 27, 29 Iron chelating compounds could have nonspecific binding affinity to the iron containing proteins or iron ions and may not be desirable from the therapeutic point of view because iron is an essential cofactor for a host of important cellular functions, including oxidative phosphorylation and arachidonic acid signaling. To our surprise, the docking simulations demonstrated that TM6089 could preferentially bind to the active site of PHD2 without chelating to the iron atom. Indeed, TM6089 is devoid of iron chelating activity in vitro. Thus, iron chelation is not a necessary intermediate of PHD inhibition. According to our knowledge, TM6089 is the first unique PHD inhibitor which stimulates HIF activity without iron chelation.
The in vivo relevance of our novel PHD inhibitors was first demonstrated by the sponge assay in mice. Previous reports have shown that the hemoglobin contents of the sponge implants and the surrounding granuloma tissue correlated with the degree of angiogenesis. 31 Accordingly, both 3,4-DHB and S956711 were shown to raise the number of vessels in the sponge. In this study, we demonstrated not only an augmented number of vessels by immunohistochemistry but also an increased hemoglobin content in the sponge after local administration of TM6008 and TM6089.
Of great interest, these effects of TM6008 and TM6089 are not restricted locally but extend to several organs. To reach this conclusion, we used a hypoxia-sensing transgenic rat expressing a hypoxia-responsive reporter vector using a HRE of the 5Ј VEGF untranslated region. 25 These transgenic rats have the unique asset to allow a sensitive and specific evaluation of HIF stimulation. As a consequence of systemic administration of TM6008 and TM6089 to these rats, expression of the reporter gene was considerably upregulated in the kidney, liver, and heart.
To extend these findings, we used less toxic TM6008 and obtained therapeutically relevant results in studies using gerbils. In gerbils, transient brain ischemia followed by reperfusion results in neuronal death in selectively vulnerable brain regions such as the hippocampal CA1 sector and caudate-putamen. The discovery that, in this model, TM6008 rescued neurons from apoptotic cell death in the CA1 hippocampus is noteworthy. Whereas TM6008 did not cross the blood-brain barrier, TM6008 protected the brain in a model of global cerebral ischemia. This is likely attributable to an increase in permeability of the blood-brain barrier, as previous reports showed that ischemic injury in this model destroys the blood-brain barrier and allows passage of compounds which do not penetrate the barrier under normal conditions. 32 Mechanisms of neuroprotection by TM6008 can theoretically be multifactorial because HIF regulates a wide range of protective genes such as those involved in erythropoiesis (EPO, transferring, and hepcidin), angiogensis (VEGF), antioxidative stress (HO-1), glycolysis (Glut-1, Glut-3, and aldolase A), and so on. Angiogenic effects of TM6008 shown by the Matrigel assays and sponge assays stimulated us to study whether enhanced angiogenesis played a role in neuronal protection in our model. However, we could not find enhanced angiogenesis in the brain of gerbils treated with TM6008 by counting VEGF-positive vessels or measuring blood flow by laser Doppler flowmetry. Therefore, it is unlikely that the protective effect of TM6008 was related to angiogenesis in the gerbil forebrain ischemia model. This may be explained by different concentrations of TM6008 among the assays. Although we could not measure the local concentrations of TM6008 in the damaged brain, it is likely that the concentration of the gerbil forebrain treated with TM6008 p.o. is lower than those obtained by local administration such as sponge assays and Matrigel assay.
We next focused on effects of TM6008 on neuronal apoptosis. Our terminal deoxynucleotidyl transferasemediated dUTP nick end-labeling (TUNEL) assays demonstrated that TM6008 decreased the number of apoptotic cells in the brain, and other potential neuroprotective mechanisms by TM6008 include antiapoptotic effects mediated by other HIF-regulated genes such as EPO, 33 VEGF, 34 and glucose transporters. 35 EPO is a pleiotropic cytokine 36 and induces neuroprotection via the antiapoptotic signaling cascades like Bcl-X L through direct binding to the Bcl-X promoter. 37 Antiapoptotic effects of VEGF contribute to reduction of ischemic brain damage in addition to its angiogenic effects. 38 The glucose transporter GLUT-1 is also positively regulated through HIF-1␣, and the microinfusion of virus vectors bearing the GLUT-1 isoform into the brain tissue reduced seizure-induced 39 and ischemic neuronal damage in vivo. 40 However, our immunohistochemical analysis could not demonstrate upregulation of these genes. In contrast, we observed upregulation of Glut-3. Glut-3 is also regulated by HIF, 41 and recent studies suggested a critical role of Glut-3 in protecting against a decline in brain glucose uptake under ischemic conditions. 42 These results fit with the observations collected during various therapeutic strategies related to HIF target genes. For instance, cobalt chloride has been used as a conventional HIF stabilizer. It is generally believed to replace the iron present in PHD, but recent studies demonstrated that cobalt also depletes intracellular ascorbate, 28 a substrate of PHD. Cobalt is effective in a variety of hypoxia-related disorders including cerebrovascular disease. 23, 43, 44 In addition to PHD, there are other factors regulating the HIF stability/activity. Factorinhibiting-HIF (FIH) hydroxylates regulates HIF activation via controlling CBP/p300 recruitment. The phosphoinositide 3-kinase (PI3K)/Akt pathway and the protein kinase C signaling have also been implicated in the regulation of HIF-␣. Whether these pathways can be a good target for therapeutic approaches is a future subject to be pursed.
The protective effect of TM6008 against ischemia-induced cerebral lesions suggested its potential usefulness in other ischemic disorders such as cardiac or kidney diseases. It should not be forgotten that HIF stimulation acts as a general switch for several proteins such as VEGF, erythropoietin, etc. Although these proteins are protective under hypoxic conditions, recent demonstration that both erythropoietin and VEGF accelerates diabetic retinopathy independently 45 should call for caution. Their administration during several months warrants long-term experimental studies before concluding to its safety. On the other hand, the short-term use of PHD inhibitors for acute hypoxic damage will probably prove safe. 
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Supplemental Methods
Chemical library
Our chemical library comprised 37 synthesis compounds by purchased from 
Transition metal chelation
Fifteen µl of 50 µM CuCl 2 and 30 µl of various concentrations of the tested compound were pre-incubated in 1.38 ml phosphate buffer at 30 °C for 5 min. The reaction was initiated by the addition of 75 µl of 10 mM ascorbic acid (final concentrations of CuCl 2 and ascorbic acid 500 nM and 500 µM, respectively).
Incubation lasted from 0 and 60 min at 30 °C so as to allow kinetic reaction studies.
Ascorbic acid content was determined on a reverse-phase high performance liquid chromatography (HPLC) with absorbance detection at 244 nm. 
Toxicity and pharmacokinetics
